Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point ...

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...

Restoring sight after whole human eye transplant remains a long-term goal, and the optic nerve is the limiting factor, ...

Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose ...

In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye ...

Innovation in therapeutics has a lot on the horizon, he said, but all of those drugs and innovations can only be delivered by ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight. Dedania ...